298 related articles for article (PubMed ID: 16904789)
1. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
Presta LG
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789
[TBL] [Abstract][Full Text] [Related]
2. Molecular engineering and design of therapeutic antibodies.
Presta LG
Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of engineered antibodies.
Hwang WY; Foote J
Methods; 2005 May; 36(1):3-10. PubMed ID: 15848070
[TBL] [Abstract][Full Text] [Related]
4. [Transgenesis and humanization of murine antibodies].
Cogné M; Duchez S; Pascal V
Med Sci (Paris); 2009 Dec; 25(12):1149-54. PubMed ID: 20035696
[TBL] [Abstract][Full Text] [Related]
5. Protein engineering of antibodies.
Sandhu JS
Crit Rev Biotechnol; 1992; 12(5-6):437-62. PubMed ID: 1423650
[TBL] [Abstract][Full Text] [Related]
6. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
7. Immunotechnological trends in radioimmunotargeting: from 'magic bullet' to 'smart bomb'.
Hazra DK; Britton KE; Lahiri VL; Gupta AK; Khanna P; Saran S
Nucl Med Commun; 1995 Feb; 16(2):66-75. PubMed ID: 7731620
[TBL] [Abstract][Full Text] [Related]
8. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
9. [Progression and direction of humanized antibody research].
Lin Y; Yan XY
Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
[TBL] [Abstract][Full Text] [Related]
10. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.
Dimasi N; Gao C; Fleming R; Woods RM; Yao XT; Shirinian L; Kiener PA; Wu H
J Mol Biol; 2009 Oct; 393(3):672-92. PubMed ID: 19699208
[TBL] [Abstract][Full Text] [Related]
11. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
12. Development of humanized antibodies as cancer therapeutics.
Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
14. Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.
Qian W; Wang L; Li B; Wang H; Hou S; Hong X; Zhang D; Guo Y
Biochem Biophys Res Commun; 2008 Mar; 367(2):497-502. PubMed ID: 18190781
[TBL] [Abstract][Full Text] [Related]
15. Design of humanized antibodies: from anti-Tac to Zenapax.
Tsurushita N; Hinton PR; Kumar S
Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
[TBL] [Abstract][Full Text] [Related]
16. Selection, design, and engineering of therapeutic antibodies.
Presta LG
J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
[TBL] [Abstract][Full Text] [Related]
17. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
18. [Immunogenicity of therapeutic antibodies].
Stas P; Lasters I
Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681
[TBL] [Abstract][Full Text] [Related]
19. Historical development of monoclonal antibody therapeutics.
Nissim A; Chernajovsky Y
Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antibodies--delivering the promise?
Hale G
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):633-9. PubMed ID: 16822575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
